Recombinant Human LYPD8(Leu20-Asn215) fused with Fc of Human IgG1 at C-terminal was expressed in CHO.
Ly6/PLAUR domain containing 8 (LYPD8), is a GPI-linked protein with structural similarity to the urokinase-type plasminogen activator receptor (uPAR). Mature human LYPD8 contains one uPAR/Ly6 domain and a Ser/Thr/Pro-rich (STP) region that may serve as a target for protease mediated shedding as has been shown for the related C4.4A/LYPD3 molecule. Mature human LYPD8 shares 40% amino acid sequence identity with mouse and rat LYPD8.
Predicted N Terminal:
Lyophilized from a 0.2 μm filtered solution in PBS.
Measured by its binding ability in a functional ELISA. When Recombinant Human LYPD8 Fc Chimera is coated at 2 µg/mL, Recombinant Human Galectin‑3 binds with a typical ED50 = 90-540 ng/mL.
Predicted Molecular Mass: 48 kDa;SDS-PAGE: 85-100 kDa, reducing conditions.
<0.10 EU per 1 μg of the protein by the LAL method.
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Avoid repeated freeze-thaw cycles.12 months from date of receipt, -20 to -70 centigrade as supplied.1 month, 2 to 8 centigrade under sterile conditions after reconstitution.3 months, -20 to -70 centigrade under sterile conditions after reconstitution.
Reconstitute at 500 μg/mL in PBS.